TARS NASDAQ
Credit Risk of going bust: lower than 82% of companies Debt: 2.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.15 (down 99.8%), Tarsus Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $88.7M against a stock market value of $3.31B.
Distance to default 10.09 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $36.4M (short-term plus half of long-term), stock volatility 44.7%; Altman Z'' 2.70. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Irvine, CA 92618
US
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| PYOTT DAVID E I | M-Exempt | 201 | — | 2026-09-15 |
| PYOTT DAVID E I | M-Exempt | 201 | — | 2026-09-15 |
| YARNO WENDY L | M-Exempt | 302 | — | 2026-09-15 |
| YARNO WENDY L | M-Exempt | 302 | — | 2026-09-15 |
| LINK WILLIAM J PHD | M-Exempt | 201 | — | 2026-09-15 |